The ascendancy of Viagra and its influence on the pharmaceutical landscape presents a intricate question for shareholders. While the early sales data were impressive, the intellectual property has ended, leading to a flood of copycat alternatives that are eroding revenue. Moreover, the market is facing issues related to demographic trends and shift